Carod-Artal Francisco Javier
Neurology Department, Raigmore Hospital, Inverness, UK; Universitat Internacional de Catalunya, Barcelona, Spain.
J Pain Res. 2014 Apr 8;7:185-94. doi: 10.2147/JPR.S61819. eCollection 2014.
In the last decade, several diagnostic criteria and definitions have been proposed for chronic migraine (CM). The third edition of the International Classification of Headache Disorders-3 beta, published in 2013, has revised CM diagnostic criteria. CM is defined as "headache occurring on 15 or more days per month for more than 3 months, which has the features of migraine headache on at least 8 days per month." Patients who meet the criteria for CM and for medication-overuse headache should be given both diagnoses. Worldwide, CM prevalence ranges 1%-3%, and its incidence has been estimated to be 2.5% per year. CM is associated with disability and poor quality of life. Modifiable risk factors include (among others): migraine progression (defined as an increase in frequency and severity of migraine attacks); medication and caffeine overuse; obesity; stressful life events; and snoring. CM patients have a significantly higher frequency of some comorbid conditions, including chronic pain, psychiatric disorders, respiratory illness, and some vascular risk factors. Management includes identification and control of comorbidities and risk factors that predispose to CM; treatment and prevention for medication overuse; early treatment for migraine attacks; and an adequate preventive therapy for CM. Several randomized controlled clinical trials have shown the efficacy of topiramate, amitriptyline, onabotulinumtoxinA, and cognitive-behavioral therapy in CM.
在过去十年中,已经提出了几种慢性偏头痛(CM)的诊断标准和定义。2013年出版的《国际头痛疾病分类第三版-3 beta》修订了CM的诊断标准。CM被定义为“每月15天或更多天数出现头痛,持续超过3个月,且每月至少8天具有偏头痛的特征”。符合CM标准且符合药物过度使用性头痛标准的患者应同时给予这两种诊断。在全球范围内,CM的患病率为1%-3%,其发病率估计为每年2.5%。CM与残疾和生活质量差有关。可改变的风险因素包括(但不限于):偏头痛进展(定义为偏头痛发作频率和严重程度增加);药物和咖啡因过度使用;肥胖;生活压力事件;以及打鼾。CM患者某些合并症的发生率明显更高,包括慢性疼痛、精神障碍、呼吸系统疾病和一些血管危险因素。管理措施包括识别和控制易患CM的合并症和风险因素;治疗和预防药物过度使用;偏头痛发作的早期治疗;以及对CM进行充分的预防性治疗。几项随机对照临床试验已经证明托吡酯、阿米替林、A型肉毒毒素和认知行为疗法在CM治疗中的有效性。